Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relugolix tablets for heavy menstrual bleeding associated with uterine fibroids (Phase III, China)
CTR20241844Phase 3Active
- Sponsor
- Qilu Pharmaceutical
- Start
- Apr 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of tissue-plasminogen activator in Fibromyoma (LM), sponsored by Qilu Pharmaceutical. Started Apr 2025; status: active.
02
Drugs
tissue-plasminogen activator
03
Conditions
Fibromyoma (LM)
Beyond the preview
Go deeper on CTR20241844.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20241844.